April 11, 2019 09:59 AM EDTUpdated May 30, 12:13 PM
R&D

Bris­tol-My­ers de­tails its fail­ure on Check­mate 451, high­light­ing a bleak fu­ture for their check­point com­bo

John Carroll

Editor & Founder

We found out last fall that Bris­tol-My­ers Squibb’s com­bi­na­tion of its PD-1/CT­LA-4 drugs Op­di­vo and Yer­voy failed to work as a main­te­nance ther­a­py for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times